Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype

James R. Johnson; Stephen B. Porter; Brian D. Johnston; Paul Thuras

doi:10.1128/AAC.02403-15

Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype

James R. Johnson, Stephen B. Porter, Brian D. Johnston, Paul Thuras

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Eravacycline is a novel broad-spectrum fluorocycline with potent Gram-negative activity, including for multidrug-resistant strains. Among 472 Escherichia coli clinical isolates from 24 Veterans Affairs medical centers (in 2011), divided equally as susceptible versus resistant to fluoroquinolones, broth microdilution eravacycline MICs were distributed unimodally, ranging from 0.03 to 1.0 μg/ml (MIC₅₀ of 0.125 μg/ml, MIC₉₀ of 0.25 μg/ml). Eravacycline MICs were μ2-fold higher among fluoroquinolone-resistant, gentamicin-resistant, multidrug-resistant, and sequence type 131 (ST131) isolates (P 0.01 for each comparison).

Original language	English (US)
Pages (from-to)	1888-1891
Number of pages	4
Journal	Antimicrobial agents and chemotherapy
Volume	60
Issue number	3
DOIs	https://doi.org/10.1128/AAC.02403-15
State	Published - Mar 2016

Bibliographical note

Publisher Copyright:
© 2016, American Society for Microbiology. All Rights Reserved.

Publisher link

10.1128/AAC.02403-15

Find It

Find It at U of M Libraries

Cite this

Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype. / Johnson, James R.; Porter, Stephen B.; Johnston, Brian D. et al.
In: Antimicrobial agents and chemotherapy, Vol. 60, No. 3, 03.2016, p. 1888-1891.

Research output: Contribution to journal › Article › peer-review

@article{462ba25b2bfd4655991491e1d2b4a285,

title = "Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype",

abstract = "Eravacycline is a novel broad-spectrum fluorocycline with potent Gram-negative activity, including for multidrug-resistant strains. Among 472 Escherichia coli clinical isolates from 24 Veterans Affairs medical centers (in 2011), divided equally as susceptible versus resistant to fluoroquinolones, broth microdilution eravacycline MICs were distributed unimodally, ranging from 0.03 to 1.0 μg/ml (MIC50 of 0.125 μg/ml, MIC90 of 0.25 μg/ml). Eravacycline MICs were μ2-fold higher among fluoroquinolone-resistant, gentamicin-resistant, multidrug-resistant, and sequence type 131 (ST131) isolates (P 0.01 for each comparison).",

author = "Johnson, {James R.} and Porter, {Stephen B.} and Johnston, {Brian D.} and Paul Thuras",

year = "2016",

month = mar,

doi = "10.1128/AAC.02403-15",

language = "English (US)",

volume = "60",

pages = "1888--1891",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype

AU - Johnson, James R.

AU - Porter, Stephen B.

AU - Johnston, Brian D.

AU - Thuras, Paul

PY - 2016/3

Y1 - 2016/3

N2 - Eravacycline is a novel broad-spectrum fluorocycline with potent Gram-negative activity, including for multidrug-resistant strains. Among 472 Escherichia coli clinical isolates from 24 Veterans Affairs medical centers (in 2011), divided equally as susceptible versus resistant to fluoroquinolones, broth microdilution eravacycline MICs were distributed unimodally, ranging from 0.03 to 1.0 μg/ml (MIC50 of 0.125 μg/ml, MIC90 of 0.25 μg/ml). Eravacycline MICs were μ2-fold higher among fluoroquinolone-resistant, gentamicin-resistant, multidrug-resistant, and sequence type 131 (ST131) isolates (P 0.01 for each comparison).

AB - Eravacycline is a novel broad-spectrum fluorocycline with potent Gram-negative activity, including for multidrug-resistant strains. Among 472 Escherichia coli clinical isolates from 24 Veterans Affairs medical centers (in 2011), divided equally as susceptible versus resistant to fluoroquinolones, broth microdilution eravacycline MICs were distributed unimodally, ranging from 0.03 to 1.0 μg/ml (MIC50 of 0.125 μg/ml, MIC90 of 0.25 μg/ml). Eravacycline MICs were μ2-fold higher among fluoroquinolone-resistant, gentamicin-resistant, multidrug-resistant, and sequence type 131 (ST131) isolates (P 0.01 for each comparison).

UR - http://www.scopus.com/inward/record.url?scp=84960408705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960408705&partnerID=8YFLogxK

U2 - 10.1128/AAC.02403-15

DO - 10.1128/AAC.02403-15

M3 - Article

C2 - 26666925

AN - SCOPUS:84960408705

SN - 0066-4804

VL - 60

SP - 1888

EP - 1891

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 3

ER -

Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this